A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis.

Trial Profile

A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Dirucotide (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MINDSET-01
  • Most Recent Events

    • 09 Sep 2009 Efficacy results have been presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 27 Mar 2009 Additional locations Bulgaria, Poland, Russia, Serbia, Slovakia, Ukraine reported by ClinicalTrials.gov.
    • 27 Mar 2009 Planned end date changed to 1 Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top